As per the research report, the size of the Europe Intravenous Ibuprofen Market was valued at USD 1.82 billion in 2020 and estimated to be growing at a CAGR of 19.23%, to reach USD 4.38 billion by 2025 during the forecast period 2020-2025.
Ibuprofen is a Non-steroidal anti-inflammatory drug used to treat pain and fever which can be causative of a disease, trauma or any major operation. In an intravenous form, the drug has a faster onset of action as compared to other forms. IV Ibuprofen is used to manage acute and post-operative pain.
Due to its faster onset of action and fast results, the market is expected to grow at a rapid rate during the forecast period. As it has been approved for pediatric use, the market is further expected to propel. Due to increased incidence of cardiovascular diseases, cancer, and fever coupled with the shifting trend to non-opioid drugs is further driving the market growth. However, the side effects associated with the use of ibuprofen and the lengthy approval processes are hampering the market growth.
This research report segmented and sub-segmented into the following categories:
Europe is predicted to grow at a substantial rate.
Key players operating in the Europe Intravenous Ibuprofen Market profiled in this report are Cumberland Pharmaceuticals Inc., Alveda Pharmaceuticals, Inc., CSL Limited, Sandor Medicaids Pvt Ltd., Germin MED, Grifols S.A., Harbin Gloria Pharmaceuticals Co., Ltd., Al Nabeel International Ltd., PT. Soho Industri Pharmasi, and Laboratorios Valmorca, C.A.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Age group
5.1.4 Y-o-Y Growth Analysis, By age group
5.1.5 Market Attractiveness Analysis, By age group
5.1.6 Market Share Analysis, By age group
5.2.4 Y-o-Y Growth Analysis, By Indication
5.2.5 Market Attractiveness Analysis, By Indication
5.2.6 Market Share Analysis, By Indication
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By age group
220.127.116.11 By indication
6.1.4 Market Attractiveness Analysis
18.104.22.168 By Geographical Area
22.214.171.124 By age group
126.96.36.199 By indication
6.1.5 Market Share Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By age group
220.127.116.11 By indication
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Cumberland Pharmaceuticals Inc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Alveda Pharmaceuticals, Inc.
8.3 CSL Limited
8.4 Sandor Medicaids Pvt Ltd.
8.5 Germin MED
8.6 Grifols S.A.
8.7 Harbin Gloria Pharmaceuticals Co.Ltd.
8.8 Al Nabeel International Ltd.
8.9 Laboratorios Valmorca, C.A.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures